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ABSTRACT 
The aim of the present study is to formulate and evaluate the transdermal patch of  Hesperidin. In the present study, transdermal patch of  
Hesperidin were prepared by using HPMC E 5, Eudragit S 100 as a polymer, Dibutyl phthalate as a plasticizer and glycerin as a lubricant. Nine 
batches (F1-F9) were prepared by solvent evaporation method using methanol and chloroform in ratio 1:1 as a solvent. The prepared 
transdermal patches were evaluated on the basis of different parameters like weight, thickness, folding endurance, percent moisture content, 
drug content , in vitro drug release study. To confirm the optimised batch, the data were computed in design expert software. And it was 
concluded that the prepared formulation F5 batch showed highest percent of drug release. 
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INTRODUCTION 
Transdermal delivery system allows delivery of drug into the 
systemic circulation via skin layers at a controlled rate. 
These systems are easy to apply and remove. This approach 
of drug delivery is more pertinent in case of chronic 
disorders which require long-term dosing to maintain 
therapeutic drug concentration [1-2]. The transdermal route 
of drug delivery has gained popularity because large number 
of drugs can be delivered by this route to treat various 
diseases. Transdermal patches were first developed in the 
1970s and the first was approved by the FDA in 1979 for the 
treatment of motion sickness [3]. 
Hesperidin is the major flavanone glycoside in sweet orange 
and lemon obtained as an abundant product of Citrus 
cultivation. Hesperidin has antioxidant, anti-inflammatory, 
cholesterol-lowering properties. It is known to reduce 
permeability and fragility of capillary walls. The bioavailable 
formulations of  this bioflavonoid may prove to be an 
effective treatment for many blood vessel disorders like 
haemorrhoid, varicose veins, venous stasis etc. In all these 
diseases proper therapeutic treatment is not widely 
available. As a result patient suffers until the disease 
aggravates to the level of surgery. For improving therapeutic 
efficacy of hesperidin it is required to identify the problems 
associated with its bioavailability in order to develop various 
formulations which can prove to be effective to treat various 
symptoms of venous diseases at early stage[4-7]. Hesperidin 
is reported to be unstable at gastric pH where it undergoes 
hydrolysis into aglycone hesperidin and enzymatic 
degradation. Hesperidin has a lower bioavailability by its 
traditional oral route (tablet, film coated tablet) and its 
gastric absorption is greatly affected by food intake and high 
acidic pH in the GI track[8] 
MATERIAL 
Extract of citrus peel, HPMC, Eudragit S 100, Dibutyl 
phthalate, Glycerin, Potassium dihydrogen orthophosphate,  
Sodium hydroxide. 
METHOD[9-10] 
In the present study patch of  Hesperidin were prepared by 
using solvent evaporation technique and evaluated for 
various parameters. Transdermal patch of hesperidin were 
prepared by using HPMC E5 and Eudragit as a polymer, 
Dibutyl phthalate as a plasticizer, glycerin as a lubricant, 
Chloroform:Methanol as a solvent. Composition of 
formulation decided as per 32 factorial design. 
Concentrations of  HPMC E5 and Eudragit S-100 taken as 
independent variables at three levels code as (-1,0,+1) 
respectively (Table 2). Composition of all formulations as per 
factorial design shown (Table no-3). Polymer HPMC E5 and 
Eudragit S 100 were mixed in a solvent mixture of 
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chloroform and methanol (ratio - 1:1 ) and stirred on 
magnetic stirrer till a clear liquid solution is obtained. 
Specified quantity (500mg) of Citrus peel extract is added in 
this solution and this mixture was stirred again and dibutyl 
phthalate was added as a plasticizer. This mixture was 
stirred for 10 mins and then sonicated in bath sonicator for 
15 mins. The mixture was poured in to petri plates which is 
lubricated with glycerin of and mixture were kept for drying 
at room temperature for 24 hrs.  
 
Table 1: Coded factor levels for optimization runs of 32 factorial 
Formulation 
Codes 
Trial          
Number 
Coded Factor Levels  
  HPMC E5 Eudragit S 100 
F1 1 -1 -1 
F2 2 -1 0 
F3 3 -1 +1 
F4 4 0 -1 
F5 5 0 0 
F6 6 0 +1 
F7 7 +1 -1 
F8 8 +1 0 
F9 9 +1 +1 
 
Table 2: Composition of all formulations as per design of experiments 
Formulation   Contents    
 Citrus peel 
extract  (mg) 
HPMC E5 (mg) Eudragit 100 
(mg) 
Dibutyl phthalate 
(mg) 
Methanol: 
Chloroform 
F1 500 300 300 120 1.1 
F2 500 300 400 120 1.1 
F3 500 300 500 120 1.1 
F4 500 450 300 120 1.1 
F5 500 450 400 120 1.1 
F6 500 450 500 120 1.1 
F7 500 600 300 120 1.1 
F8 500 600 400 120 1.1 
F9 500 600 500 120 1.1 
 
Evaluation of transdermal patches[11-19] 
Weight uniformity 
The weight of 1 patch (1 cm2) from each batch was 
determined using an  electronic balance. 
Thickness 
The thickness of the formulated patches was measured using 
by using Vernier Caliper and average thickness was 
calculated. The average thickness of all prepared 
transdermal patches ranged from 0.36 to 0.45 mm. 
Surface pH 
The surface pH of the patch was determined to ensure that it 
does  not cause any irritation to the skin. pH was measured 
using a pH meter ( Deluxe pH meter 101, India). Firstly the 
surface of the patch moistened and the electrode probe of 
the pH meter was placed in close contact with the wet 
surface of the patch and pH was recorded 
Surface pH for formulation F1–F9 was found in the range 6.4 
to 7.3 which is close to the skin pH (6.5-7.4) shown in (Table 
4). 
Swelling studies 
swelling index study was performed to study the hydration 
characteristics of the film. 1 cm2 patches were weighed 
separately (initial weight= W1) and placed in petri plates 
containing 6 ml distilled water. The swollen films were 
weighed individually at regular time intervals up to 25 
minutes (Final weight = W2). 
Swelling index of each system was calculated using the 
following formula: 
Percentage moisture content = [Finnal weight- Initial 
weight/ Initial weight] ×100. 
Swelling behaviour of patch as a function of time is 
illustrated in the following figure no-1. 
Percent moisture content 
The films were kept in desiccator for 24 hours and the 
moisture content was calculated by the following formula 
Percentage moisture content = [Initial weight- Final weight/ 
Final weight] ×100. The percent moisture content was found 
to be in range 2.05% - 4.55%. This shows that the moisture 
content was between the limits.(Table 3). 
Folding endurance 
The patches were repeatedly folded in the same place 300 
times or until they broke, which ever was less, to determine 
their folding endurance. All formulations shown folding 
endurance values ranging from 200-300, which indicates the 
film is highly flexible. (Table 4). 
Drug content 
The drug content was determined using HPTLC. Patches of 1 
cm2 were cut and placed in test tubes containing 1 ml of 
DMSO and 9 ml methanol for 24 hrs to extract the drug. 
This solution was filtered and further diluted with methanol 
and analysed by HPTLC  at a wavelength of 283 nm. Drug 
content was calculated using equation obtained from the 
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standard calibration curve  of Hesperidin. The drug content 
ranged from 97.00 % to 98.63 %.(Table 4). 
In-vitro drug release studies 
The release pattern of hesperidin from the patches was 
determined using a Franz diffusion cell and Nylon 66 
membrane (pore size 0.45µm), 8.0 ml of phosphate buffer 
pH 7.4 was placed in the receiver compartment of the Franz 
diffusion cell. Patches of 1 cm2 area were placed on 
membrane which was positioned between the donor and 
receiver compartment. The temperature of the system was 
maintained at 37.0 ± 0.5oC and the buffer was continuously 
stirred using a magnetic bead for uniform distribution of the 
diffused drug. 1 ml of sample were withdrawn at 1 hour time 
intervals up to 6 hours and analysed by HPTLC using mobile 
phase Ethyl acetate: methanol: water at a wavelength of 283 
nm. 
F5 batch showed highest diffusion of Hesperidin within 6 
hours (Fig 4). 
 
 
 
Fig 3: Franz Diffusion cell Setup 
 
Optimization 
Optimization of the transdermal patches was done using a 32 
factorial design by taking the concentrations of HPMC E5  
and Eudragit S-100 as the independent variables X1 and X2 
respectively and flux and folding endurance as the responses 
variables Y1, Y2 respectively. (Table 6) 
Analysis of experimental results 
Analysis of experimental results was done by using the 
Design of Expert. After filling the data in the design, 
quadratic model were suggested to run the design. The 
regression coefficient, standard deviation, F-value and P-
value for flux, and folding endurance were obtained from 
ANOVA. 
Effect of  formulation variables on flux 
The observed flux, from permeation studies,  for all the 
batches was found to be in the range 14.2-19.05 (µg/h/cm2) 
The Model F-value of 39.14 implies the model is significant. 
There is only a 0.62% chance that an F-value this large could 
occur due to noise. P-values less than 0.0500 indicate model 
terms are significant. In this case B, A², B² are significant 
model terms. Values greater than 0.1000 indicate the model 
terms are not significant.ve a positive effect on the flux in 
combined form. 
The final equation of flux in terms of coded factors is as 
follows: 
 Flux = +15.37-0.1233 A+1.65 B+ -0.0350 AB+ -1.03 A^2B  
+1.85 AB^2 
Effect of formulation variables on folding endurance 
Folding endurance is an important property which ensures 
proper flexibility to the patch and resistance to the external 
stress and rough handling. 
The Model F-value of 29.01 implies the model is significant. 
There is only a 0.96% chance that an F-value this large could 
occur due to noise. 
P-values less than 0.0500 indicate model terms are 
significant. In this case A, B, B² are significant model terms. 
Values greater than 0.1000 indicate the model terms are not 
significant. 
Validation of optimum design 
To obtain an optimum formula and justify the validity of the 
optimization, design expert is used. The selection criteria 
used had flux in the range 14-19 µg/hr/cm2 , and folding 
endurance  in the range 200 – 300 folds. The predicted and 
observed values were found to be in good agreement for all 
the three responses. Formulation F5 had the composition 
closest to the validation batches (HPMC E5 – 450 mg and 
Eudragit S100 – 400 mg) was selected as the optimum 
formulation.
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RESULT AND DISCUSSION 
 
Figure 1:- Swelling Study 
Table-3 Percent moisture content 
Sr. 
No. 
Formulations Initial Weight 
gm 
Final weight 
gm 
% Moisture Content 
1 F1 0.1805 0.1755 2.84 
2 F2 0.2106 0.2054 2.53 
3 F3 0.1959 0.1885 3.92 
4 F4 0.2010 0.1930 4.14 
5 F5 0.2134 0.2079 2.64 
6 F6 0.2002 0.1920 4.27 
7 F7 0.1994 0.1909 4. 45 
8 F8 0.1831 0.1760 4.03 
9 F9 0.1934 0.1864 3.75 
 
 
Fig 2:Densitogram for assay of patch 
Track 1 Blank, 2-6 Marker linearity 200-1000 ng/band,7-Extract 20000 ng/band, 8 Patch 250 ng/band. 
Table-4 Evaluation results of F1-F9 batches 
Batch F1 F2 F3 F4 F5 F6 F7 F8 F9 
Swelling index 9.52 
±0.14 
10.9 
±0.08 
14.09 
±0.06 
11.13 
±0.07 
16.33 
±0.0.04 
17.27 
±0.02 
12.62 
±0.06 
18.24 
±0.06 
20.69 
±0.02 
Thickness 
(mm) 
0.41 
±0.02 
0.39 
±0.01 
0.36 
±0.06 
0.40 
±0.06 
0.38 
±0.04 
0.40 
±0.02 
0.42 
±0.04 
0.41 
±0.02 
0.44 
±0.05 
Weight 
(mg) 
0.18 
±0.04 
0.19 
±0.03 
0.20 
±0.05 
0.21 
±0.03 
0.21 
±0.02 
0.20 
±0.06 
0.19 
±0.04 
0.18 
±0.03 
0.19 
±0.02 
Surface pH 6.56 
± 0.24 
6.59 
± 0.52 
6.57 
± 0.08 
6.58 
± 0.06 
7.0 
± 0.05 
6.52 
± 0.13 
6.55 
± 0.31 
6.59 
± 0.61 
6.54 
± 0.05 
Folding 
Endurance 
244 
± 4 
233 
± 5 
210 
± 6 
229 
± 11 
275 
± 3 
249 
± 3 
254 
± 4 
237 
± 7 
268 
± 2 
Drug content 
(%) 
97.63 
± 8.29 
97.96 
± 5.70 
96.41 
± 4.28 
90.64 
± 9.11 
98.01 
± 7.49 
96.82 
± 9.50 
95.03 
± 8.72 
96.21 
± 4.61 
95.81 
± 4.37 
Moisture content 
(%) 
2.84 
± 0.5 
2.53 
± 0.5 
3.92 
± 0.5 
4.14 
± 0.5 
2.64 
± 0.5 
4.27 
± 0.5 
4.45 
± 0.5 
4.03 
± 0.5 
3.75 
± 0.5 
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Fig 4: Densitogram for % drug release (F5 batch) 
 
Table 5: % drug release data for F5 batch 
Time (hrs) Area Concentration Amount release % Amoumt release 
0 0 0 0 0 
1 1005.5 1.75 0.14 1.80 
2 1155.0 24.39 1.95 25.02 
3 1299.5 46.12 3.69 47.31 
4 1395.2 60.61 4.85 62.17 
5 1489.9 74.86 5.99 76.79 
6 1598.9 91.32 7.31 93.66 
 
 
Fig-5: % Drug release graph of F5 batch 
 
 
Fig-6: Hesperidin diffusion from all batches. 
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Table 6: Flux and folding endurance of optimised batch 
 
Batch no. 
Variable levels in 
coded form 
Responses 
Flux 
(µg/h/cm2) 
Folding Endurance 
X1 X2 Y1 Y3 
F1 -1 -1 14.2 244 
F2 -1 0 17.5 233 
F3 -1 +1 18.0 210 
F4 0 -1 14.6 229 
F5 0 0 19.05 275 
F6 0 +1 14.23 249 
F7 +1 -1 15.52 254 
F8 +1 0 14.87 237 
F9 +1 +1 15.23 268 
 
Table 7: Response for flux 
Response F-value P-value SD R2 
Folding endurance 29.01 0.0500 4.66 
 
0.9797 
 
Table 8: Response for folding endurance 
Response F-value P-value SD R2 
Flux 39.14 0.0500 0.361 0.9849 
 
 
Fig 7: Plot for Flux. 
 
Fig 8: Plot for Folding Endurance 
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CONCLUSION 
The objective of the study was to formulate and evaluate 
transdermal patches of Hesperidin. Transdermal patches 
were formulated using a combination of two polymers, 
HPMC E5 and Eudragit S 100 by solvent evaporation 
method. Optimization was done using a 32 factorial design 
taking concentrations of  HPMC E5 and Eudragit S-100 as 
independent variables at three levels code as (-1,0,+1) 
respectively. Formulated patches were subjected to 
evaluation tests such as measurement of thickness, surface 
pH, swelling index, drug content, folding endurance,% drug 
release. Results showed that patches were prepared with 
uniform thickness which ensured uniformity of content. 
Surface pH of all patches was in the range 6.5 to 7.4 which is 
close to skin pH, hence, no skin irritation was expected. Drug 
content was found to be in the range 97.00%-98.63 %. In-
vitro drug release studies were performed using Nylon 66 
mebrane by Franz diffusion cell . Flux for all patches was 
calculated from the results of In-vitro drug release studies.  
Effect of formulation variables on the two response variables 
was studied. Flux and Folding Endurance were chosen as the 
response variables. The data obtained by experimental 
design was evaluated using Design expert. 3D response 
surfaces curves were constructed to study the effect of two 
independent variables. Batch F5 showed high folding 
endurance value (275) while others had not less than 200 
which indicate that they have good flexibility. It also showed 
the high % drug release. 
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